Biomedical Engineering Reference
In-Depth Information
8. Kalie E, Jaitin DA, Abramovich R, Schreiber G. (2007) An
interferon alpha 2 mutant optimized by phage display for
IFNAR1 binding confers specifically enhanced antitumor
activities. J. Biol. Chem. 282(15), 11602-11611.
9. Thyrell L, Arulampalam V, Hjortsberg L, Farnebo M,
Grander D, Pokrovskaja Tamm K. (2007) Interferon alpha
induces cell death through interference with interleukin 6
signaling and inhibition of STAT3 activity. Exp. Cell Res.
313(19), 4015-4024.
10. Shechter Y, Preciado-Patt L, Schreiber G, Fridkin M. (2001)
Prolonging the half-life of human interferon-alpha 2 in
circulation: Design, preparation, and analysis of (2-sulfo-9-
fluorenylmethoxycarbonyl)7- interferon-alpha 2. Proc. Natl.
Acad. Sci. U S A 98(3), 1212-1217.
11. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX,
Garcia A, et al. (2002) Pharmacokinetic and pharmaco-
dynamic studies of a human serum albumin-interferon-alpha
fusion protein in cynomolgus monkeys. J. Pharmacol. Exp.
Ther. 303(2), 540-548.
12. Perry CM, Jarvis B. (2001) Peginterferon-alpha-2a (40 kD): a
review of its use in the management of chronic hepatitis C.
Drugs 61(15), 2263-2288.
13. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta
SK, et al. (2000) Pegylated interferon-alpha2b: pharmaco-
kinetics, pharmacodynamics, safety, and preliminary efficacy
data. Hepatitis C Intervention Therapy Group. Clin. Phar-
macol. Ther. 68(5), 556-567.
14. Foster GR. (2004) Review article: pegylated interferons:
chemical and clinical differences. Aliment. Pharmacol.
Ther. 20(8), 825-830.
15. Hoofnagle JH. (2009) A step forward in therapy for hepatitis
C. N. Engl. J. Med. 360(18), 1899-1901.
16. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G,
Goncales FL, Jr., et al. (2002) Peginterferon alfa-2a plus
ribavirin for chronic hepatitis C virus infection. N. Engl. J.
Med. 347(13), 975-982.
17. Sharma SD. (2010) Hepatitis C virus: molecular biology and
current therapeutic options. Indian J. Med. Res. 131, 17-34.
18. Bacon BR, Shiffman ML, Mendes F, Ghalib R, Hassanein T,
Morelli G, et al. (2009) Retreating chronic hepatitis C with
daily interferon alfacon-1/ribavirin after nonresponse to
pegylated interferon/ribavirin: DIRECT results. Hepatology
49(6), 1838-1846.
19. Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B,
Chen G, et al. (2002) Albutropin: a growth hormone-albumin
fusion with improved pharmacokinetics and pharmaco-
dynamics in rats and monkeys. Eur. J. Pharmacol.
456(1-3), 149-158.
20. Duttaroy A, Kanakaraj P, Osborn BL, Schneider H, Pickeral
OK, Chen C. et al. (2005) Development of a long-acting
insulin analog using albumin fusion technology. Diabetes
54(1), 251-258.
21. Wang W, Ou Y, Shi Y. (2004) AlbuBNP, a recombinant B-
type natriuretic peptide and human serum albumin fusion
hormone, as a long-term therapy of congestive heart failure.
Pharm. Res. 21(11), 2105-2111.
22. van Dijkhuizen-Radersma R, Hesseling SC, Kaim PE, de
Groot K, Bezemer JM. (2002) Biocompatibility and degra-
dation of poly(ether-ester) microspheres: in vitro and in vivo
evaluation. Biomaterials 23(24), 4719-4729.
23. De Leede LG, Humphries JE, Bechet AC, Van Hoogdalem
EJ, Verrijk R, Spencer DG. (2008) Novel controlled-release
Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics,
pharmacodynamics, and tolerability in a Phase I clinical trial.
J. Interferon Cytokine Res. 28(2), 113-122.
24. Kasama K, Utsumi J, Matsuo-Ogawa E, Nagahata T, Kagawa
Y, Yamazaki S, et al. (1995) Pharmacokinetics and biologic
activities of human native and asialointerferon-beta s.
J. Interferon Cytokine Res. 15(5), 407-415.
25. Eto T, Takahashi H. (1999) Enhanced inhibition of hepatitis B
virus production by asialoglycoprotein receptor-directed
interferon. Nat. Med. 5(5), 577-581.
26. Xi K, Tabata Y, Uno K, Yoshimoto M, Kishida T, Sokawa Y,
et al. (1996) Liver targeting of interferon through pullulan
conjugation. Pharm. Res. 13(12), 1846-1850.
27. Tabata Y, Matsui Y, Uno K, Sokawa Y, Ikada Y. (1999)
Simple mixing of IFN with a polysaccharide having high
liver affinity enables IFN to target to the liver. J. Interferon
Cytokine Res. 19(3), 287-292.
28. Yuan L, Wang J, Shen WC. (2008) Lipidization of human
interferon-alpha: a new approach toward improving the deliv-
ery of protein drugs. J. Control. Release. 129(1), 11-17.
29. Aurisicchio L, Bujard H, Hillen W, Cortese R, Ciliberto G, La
Monica N, et al. (2001) Regulated and prolonged expression
of mIFN(alpha) in immunocompetent mice mediated by a
helper-dependent adenovirus vector. Gene Ther. 8(24),
1817-1825.
30. Berraondo P, Ochoa L, Crettaz J, Rotellar F, Vales A, Marti-
nez-Anso E, et al. (2005) IFN-alpha gene therapy for wood-
chuck hepatitis with adeno-associated virus: differences in
duration of gene expression and antiviral activity using intra-
portal or intramuscular routes. Mol. Ther. 12(1), 68-76.
31. Breous E, Somanathan S, Bell P, Wilson JM. (2011) Inflam-
mation causes loss of adeno-associated virus-mediated trans-
gene expression in mouse liver. Gastroenterology. 141(1),
348-57.
32. Forti N, Diament J. (2006) High-density lipoproteins:metabolic,
clinical, epidemiological and therapeutic intervention aspects.
An update for clinicians. Arq. Bras. Cardiol. 87(5), 671-679.
33. Mahley RW, Innerarity TL, Rall SC, Jr., Weisgraber KH.
(1984) Plasma lipoproteins: apolipoprotein structure and
function. J. Lipid Res. 25(12), 1277-1294.
34. Sirtori CR, Calabresi L, Franceschini G. (1999) Recombinant
apolipoproteins for the treatment of vascular diseases.
Atherosclerosis 142(1), 29-40.
35. Rothblat GH, Mahlberg FH, Johnson WJ, Phillips MC. (1992)
Apolipoproteins, membrane cholesterol domains, and the regu-
lation of cholesterol efflux. J. Lipid Res. 33(8), 1091-1097.
36. Banka CL, Bonnet DJ, Black AS, Smith RS, Curtiss LK.
(1991) Localization of an apolipoprotein A-I epitope critical
for activation of lecithin-cholesterol acyltransferase. J. Biol.
Chem. 266(35), 23886-23892.
Search WWH ::
Custom Search